Prostate News and Research

RSS

Proton therapy to treat patient’s tumor without compromising quality of life

The radiation oncologist's mantra is to deliver the maximum dose of radiation to the malignant tumor, while limiting damage to healthy surrounding tissue. In proton therapy, this balance is achieved by using proton particles, accelerated to nearly the speed of light, to mimic the shape of a tumor and effectively deposit their energy within the confines of it with sub-millimeter precision.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."

3 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

New surgical technique to maximize preservation of periprostatic anatomy

Stress urinary incontinence is one of the most feared complications of radical prostatectomy. The weighted mean continence rate immediately after catheter removal following robot-assisted laparoscopic radical prostatectomy (RALP) is 25.7%. Evidently, early recovery of urinary continence remains a challenge to be overcome. The Surgery in Motion section of the September issue of European Urology describes the surgical steps of pubovesical complex (PVC)-sparing RALP and presents the preliminary results of the technique.

3 Aug 2010

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

ARO uses Elekta VMAT system for prostate cancer patients

In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."

From Elekta 2 Aug 2010

IRIS International closes AlliedPath acquisition

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has closed the acquisition of AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics.

2 Aug 2010

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

A genome-wide study on Japanese subjects has identified 5 new genetic variations associated with prostate cancer and revealed differences and similarities between Europeans and Asians in susceptibility to the disease. Reported in Nature Genetics, the findings offer a first-ever glimpse of the genetic basis for prostate cancer susceptibility in a non-European population.

2 Aug 2010

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

No More Excuses No More Lung Cancer 5K Run/Walk comes back to Georgia

Today, Lung Cancer Alliance-Georgia announced the return of the No More Excuses No More Lung Cancer 5K Run/Walk. Taking place on Saturday, November 6, 2010, the run/walk will raise awareness for lung cancer to help reduce the stigma of the disease, expand the grassroots movement for the disease and inspire others to join the cause to increase compassion and support to all those impacted by lung cancer

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

BioCurex Inc. today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex's presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.

30 Jul 2010

Prostate basal cell can spawn tumors in prostate gland: Research

A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer, according to new studies by Howard Hughes Medical Institute (HHMI) scientists and their colleagues.

30 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Scientists develop new surgical procedure for prostate cancer using natural orifices

With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices - signaling the next step in the evolution of minimally invasive surgery.

29 Jul 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

Prostate News and Research

Proton therapy to treat patient’s tumor without compromising quality of life

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

Dendreon second-quarter revenue increases to $2.8 million

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

New surgical technique to maximize preservation of periprostatic anatomy

Study reveals potential marker for prostate cancer

ARO uses Elekta VMAT system for prostate cancer patients

IRIS International closes AlliedPath acquisition

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

Cell-of-origin for prostate cancer identified

No More Excuses No More Lung Cancer 5K Run/Walk comes back to Georgia

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

Prostate basal cell can spawn tumors in prostate gland: Research

AVEO second-quarter total revenues increase to $15.6 million

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Scientists develop new surgical procedure for prostate cancer using natural orifices

Aggressive prostate cancer patients tend to retain denser bones

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News